Get the Stockscreener App
6.46
1.07%
-0.07
After Hours:
6.37
-0.09
-1.39%
4 D Molecular Therapeutics Inc stock is traded at $6.46, with a volume of 399.07K.
It is down -1.07% in the last 24 hours and up +41.36% over the past month.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
See More
Previous Close:
$6.53
Open:
$6.54
24h Volume:
399.07K
Relative Volume:
0.38
Market Cap:
$301.70M
Revenue:
$20.72M
Net Income/Loss:
$-100.84M
P/E Ratio:
-2.4286
EPS:
-2.66
Net Cash Flow:
$-78.56M
1W Performance:
-5.69%
1M Performance:
+41.36%
6M Performance:
+44.20%
1Y Performance:
-58.40%
1-Day Range:
$6.385
$6.82
1-Week Range:
$6.385
$7.33
52-Week Range:
$2.235
$17.41
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Name
4 D Molecular Therapeutics Inc
Sector
Industry
Phone
(510) 505-2680
Address
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
6.46 | 304.97M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
389.08 | 99.27B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
586.96 | 62.28B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.18 | 59.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
707.96 | 43.34B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
300.14 | 36.72B | 3.81B | -644.79M | -669.77M | -6.24 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Nov-21-24 | Initiated | Morgan Stanley | Underweight |
| Sep-23-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Apr-15-24 | Initiated | Barclays | Overweight |
| Feb-07-24 | Resumed | Goldman | Buy |
| Oct-26-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-18-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-18-22 | Initiated | H.C. Wainwright | Buy |
| Nov-15-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-12-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-22-22 | Initiated | Jefferies | Buy |
| Jan-04-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | BofA Securities | Buy |
| Jan-05-21 | Initiated | Evercore ISI | Outperform |
| Jan-05-21 | Initiated | Goldman | Neutral |
View All
4 D Molecular Therapeutics Inc Stock (FDMT) Latest News
4D Molecular Therapeutics Inc. stock chart pattern explainedJuly 2025 Catalysts & Smart Swing Trading Alerts - Newser
Can you recover from losses in 4D Molecular Therapeutics Inc.Market Risk Summary & Entry Point Confirmation Alerts - Newser
What institutional flow reveals about 4D Molecular Therapeutics Inc.Market Growth Summary & Capital Protection Trading Alerts - Newser
Predicting 4D Molecular Therapeutics Inc. trend using moving averagesJuly 2025 Summary & Verified Momentum Watchlists - Newser
Price momentum metrics for 4D Molecular Therapeutics Inc. explainedMarket Movement Recap & High Accuracy Buy Signal Tips - Newser
Can trapped investors hope for a rebound in 4D Molecular Therapeutics Inc.2025 Top Gainers & Weekly High Return Stock Forecasts - Newser
What momentum shifts mean for 4D Molecular Therapeutics Inc.Portfolio Return Summary & Low Risk Growth Stock Ideas - Newser
Market reaction to 4D Molecular Therapeutics Inc.’s recent newsMarket Activity Recap & Risk Managed Trade Strategies - Newser
Volatility clustering patterns for 4D Molecular Therapeutics Inc.Trade Ideas & Safe Capital Preservation Plans - Newser
What indicators show strength in 4D Molecular Therapeutics Inc.Weekly Trade Review & Expert Verified Stock Movement Alerts - Newser
How to escape a deep drawdown in 4D Molecular Therapeutics Inc.2025 Market Overview & Risk Managed Trade Strategies - Newser
Will a bounce in 4D Molecular Therapeutics Inc. offer an exitPortfolio Growth Summary & Accurate Buy Signal Notifications - Newser
Is 4D Molecular Therapeutics Inc. meeting your algorithmic filter criteriaTreasury Yields & AI Enhanced Market Trend Forecasts - Newser
4D Molecular Therapeutics shares fall 5.19% premarket despite upcoming investor conferences in September. - AInvest
What technical models suggest about 4D Molecular Therapeutics Inc.’s comebackJuly 2025 Snapshot & AI Forecasted Stock Moves - Newser
4D Molecular Therapeutics Inc. Reversal Rally May Surprise Bears2025 Key Highlights & Technical Entry and Exit Alerts - beatles.ru
Why 4D Molecular Therapeutics Inc. stock attracts strong analyst attention2025 Analyst Calls & Weekly Market Pulse Updates - sisaissue.com
Using fundamentals and technicals on 4D Molecular Therapeutics Inc.Weekly Market Outlook & Weekly High Return Stock Opportunities - Newser
Technical analysis overview for 4D Molecular Therapeutics Inc. stock2025 Key Lessons & Capital Efficiency Focused Strategies - Newser
Relief Rally in 4D Molecular Therapeutics Inc. Stock — Can It Hold2025 Market WrapUp & Free Daily Entry Point Trade Alerts - newsyoung.net
Candlestick Signal Suggests Reversal in 4D Molecular Therapeutics Inc.Analyst Downgrade & Weekly Watchlist of Top Performers - 선데이타임즈
4D Molecular Therapeutics Inc. stock prediction for this weekWeekly Trade Analysis & Reliable Intraday Trade Alerts - Newser
Is 4D Molecular Therapeutics Inc. forming a reversal patternJuly 2025 Movers & High Conviction Trade Alerts - Newser
Will 4D Molecular Therapeutics Inc. price bounce be sustainableJuly 2025 Levels & Low Risk Entry Point Guides - Newser
4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Lowered to $38.00 at Roth Capital - MarketBeat
4D Molecular Therapeutics Faces Revenue Challenges Amid Complex Reimbursement Landscape - MSN
4D Molecular Therapeutics Advances Clinical Programs in Q2 2025 - TipRanks
58,900 RSUs Awarded: 4D Molecular Therapeutics Strengthens Team with New Employee Inducement Grants - Stock Titan
4 D Molecular Therapeutics Inc Stock (FDMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
8.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):